Evidence map›Paper›PMID 42233233›Full record

ArticleGigaScience2026

CPSM: an R package for cancer patient survival risk model using transcriptomics and clinical data.

Harpreet Kaur, Pijush Das, Kevin Camphausen, Uma Shankavaram

Abstract read
In one paragraph

Article in GigaScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Harpreet KaurRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-0421-8341
Pijush DasRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-9767-0016
Kevin CamphausenRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-0450-4877
Uma ShankavaramRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-9659-0284

Funding

Radiation Oncology Branch - Microarray FacilityZICBC010991 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CAMPHAUSEN, KEVIN · 2009 to 2025
$13.8M
Intramural NIH HHS ZIC BC010991
6 · The paper itself

Abstract

Traditional Kaplan-Meier curves capture aggregate survival trends within broad patient subgroups but overlook the heterogeneity of individual patients. In contrast, single-patient survival risk models bridge this gap by incorporating each patient's unique clinical, genomic, and demographic characteristics, generating personalized survival curves. These individualized visualizations enhance patient-clinician communication by translating complex statistics into intuitive, time-based visuals that are easier to interpret. However, the complexity, high dimensionality, and heterogeneity of multiomics data present significant challenges for analysis, interpretation, and model development. To address these challenges, we introduce the Cancer Patient Survival Model (CPSM), an R package designed to deliver individualized survival and risk predictions through a fully integrated, reproducible computational pipeline. CPSM includes 10 core functions organized into 4 key steps: (i) data preprocessing and normalization, (ii) feature selection, (iii) survival risk group prediction modeling, and (iv) visualization and nomogram construction. We demonstrate the utility of CPSM using publicly available datasets from The Cancer Genome Atlas for 4 cancer types: glioblastoma multiforme (GBM), acute myeloid leukemia (LAML), pancreatic adenocarcinoma (PAAD), and breast invasive cancer (BRCA). CPSM efficiently handles high-dimensional datasets with over 60,000 RNA transcripts and diverse clinical variables, enabling robust and interpretable individualized survival predictions under varying data conditions. Model performance was evaluated using repeated cross-validation with uncertainty quantification, ensuring robust and reliable estimates in high-dimensional, small-sample settings. In summary, CPSM provides an efficient, user-friendly, end-to-end solution for integrating patient data and generating personalized survival and risk predictions. Its integrated visual tools enhance interpretability and support more informed clinical decision-making. The package is freely available on Bioconductor (https://bioconductor.org/packages/devel/bioc/html/CPSM.html) and GitHub (https://github.com/hks5august/CPSM).

Indexed as

Computational BiologyGene Expression ProfilingNeoplasmsSoftwareTranscriptomeHumansPrognosisSurvival Analysisbioinformaticsbiomarkercancerpackagepredictionsurvival

Identifiers

PMID42233233
PMCPMC13289734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.